CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.
Inclusion Criteria:
Male or female.
Age 18 years or above at the time of signing the informed consent.
Have an established diagnosis of ATTR-CM (wild-type ATTR [ATTRwt] or variant ATTR [ATTRv]), with cardiac amyloid infiltration, increased left ventricular (LV) wall thickness, and HF.
Note: Target ATTRv recruitment is approximately 15 percent of the study population.
a. Cardiac amyloid infiltration demonstrated by: i. Cardiac biopsy positive for TTR amyloid, OR ii. Grade 2 or 3 cardiac uptake at pyrophosphate (PYP)/diphosphono-1,2-propanodicarboxylic acid (DPD)/ hydroxymethylene diphosphonate (HMDP) nuclear medicine imaging with single-photon emission computed tomography (SPECT) or SPECT/CT (preferably) combined with an extracardiac biopsy positive for TTR amyloid, OR iii. Grade 2 or 3 cardiac uptake at PYP/DPD/HMDP nuclear medicine imaging with SPECT or SPECT/CT (preferably) combined with normal serum free light chain ratio, and negative serum and urine protein electrophoresis with immunofixation (SPIE & UPIE)/or mass spectrometry based methods including mass fixation).
Notes:
Non-invasive diagnostic pathway will be confirmed by a centralised expert review.
Bone tracer nuclear medicine imaging with SPECT or SPECT/CT (preferably) will be conducted using 99m-technetium (Tc)-labelled pyrophosphate (99mTc-PYP), 99mTc-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD), or 99mTc-labeled hydroxymethylene diphosphonate (99mTc-HMDP).
The eGFR adjusted acceptable serum free light chain ratio.
Patients with Grade 2 or 3 cardiac uptake at PYP/DPD/HDMP nuclear imaging with SPECT or SPECT/CT (preferably) and evidence of monoclonal gammopathy of undetermined significance (MGUS; based on serum and urine protein electrophoresis and serum free light chains) will require endomyocardial biopsy with typing using mass spectrometry or immunohistochemistry to confirm presence of TTR protein in tissue.
Timing of serum free light chain ratio, SPIE, UPIE and mass spectrometry-based methods including mass fixation should be within 12 months of SPECT or SPECT/CT nuclear imaging.
b. Increased LV wall thickness, as assessed by centralised review of echocardiography, showing interventricular septal wall thickness greater than or equal to 12 millimeter (mm).
c. Chronic HF (New York Heart Association [NYHA] Class I-IV): i. At least 1 documented hospitalisation for HF, OR ii. History of HF manifested by signs or symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath, signs of pulmonary congestion on x-ray or auscultation, or peripheral oedema that required or requires ongoing treatment with a diuretic).
Expected to be on stable cardiovascular medical therapy (defined as no greater than 50 percent dose adjustment and no categorical changes of medications), with the exception of diuretics, 4 weeks prior to the randomisation visit.
Completed more than 50 meters on the 6MWT at screening.
Exclusion Criteria:
clinicaltrials@novonordisk.com(+1) 866-867-7178
La Jolla, California 92037, United States
Los Angeles, California 90033, United States
Los Angeles, California 90048, United States
Pasadena, California 91105, United States
San Francisco, California 94143, United States
Washington D.C., District of Columbia 20010-3017, United States
Chicago, Illinois 60611, United States
Indianapolis, Indiana 46202, United States
New Orleans, Louisiana 70112, United States
Baltimore, Maryland 21201, United States
The Bronx, New York 10467-2401, United States
Cincinnati, Ohio 45219-2906, United States
Hershey, Pennsylvania 17033, United States
Lancaster, Pennsylvania 17603, United States
Philadelphia, Pennsylvania 19104, United States
Dallas, Texas 75246, United States
Murray, Utah 84107, United States
Falls Church, Virginia 22042, United States
Spokane, Washington 99201, United States
Caba, 1425, Argentina
Corrientes, W3400AMZ, Argentina
Liverpool, New South Wales 2170, Australia
Woolloongabba, Queensland 4102, Australia
Adelaide, South Australia 5000, Australia
Joondalup, Western Australia 6027, Australia
Brussels, Anderlecht 1070, Belgium
Waterschei-Zwartberg, Limburg 3600, Belgium
Sint-Gillis-Dendermonde, Oost-Vlaanderen 9200, Belgium
Roeselare, 8800, Belgium
Salvador, Estado de Bahia 40170-130, Brazil
BrasĆlia, Federal District 70200-730, Brazil
Belo Horizonte, Minas Gerais 30150-274, Brazil
UberlĆ¢ndia, Minas Gerais 38400-500, Brazil
Curitiba, ParanĆ” 80230-130, Brazil
Recife - PE, Recife - PE 50070-490, Brazil
Campinas, SĆ£o Paulo 13087-567, Brazil
RibeirĆ£o Preto, SĆ£o Paulo 14026-020, Brazil
RibeirĆ£o Preto, SĆ£o Paulo 14049-900, Brazil
Salvador, 40170-130, Brazil
SĆ£o Paulo, 05403-900, Brazil
Greater Sudbury, Ontario P3E 5J1, Canada
London, Ontario N6A 5A5, Canada
Fuzhou, Fujian 350005, China
Guangzhou, Guangdong 510080, China
Harbin, Heilongjiang 150001, China
Zhengzhou, Henan 450052, China
Wuhan, Hubei 430030, China
Nanjing, Jiangsu 210029, China
Liaoning, Liaoning 110004, China
Shanghaishi, Shanghai Municipality 200025, China
Hangzhou, Zhejiang 310003, China
Chongqing, 400000, China
Ostrava-Poruba, 708 52, Czechia
Prague, 12808, Czechia
Copenhagen, Capital Region 2100, Denmark
Chambray-lĆØs-Tours, 37170, France
La Roche-sur-Yon, 85925, France
Marseille, 13385, France
Metz-Tessy, 74370, France
Montpellier, 34090, France
Paris, 75015, France
Toulouse, 31059, France
WĆ¼rzburg, 97078, Germany
Dublin, D08 F2H7, Ireland
Ancona - Torrette, 60126, Italy
Brescia, 25123, Italy
Florence, 50134, Italy
Milan, 20132, Italy
Pavia, 27100, Italy
Pisa, 56126, Italy
Rome, 186, Italy
Uwajima-shi, Ehime 798-8510, Japan
Kitakyushu, Fukuoka 807-8556, Japan
Kurume-shi, Fukuoka 830-0011, Japan
Nankoku-shi, Kochi 783-8505, Japan
Matsumoto, Nagano 390-8621, Japan
Bunkyo-ku, Tokyo 113-8603, Japan
Yamaguchi Prefecture, Yamaguchi 755-8505, Japan
Kumamoto, 861-4193, Japan
Poznan, 61-848, Poland
Warsaw, 04-628, Poland
Seongnam-si, Gyeonggi-do 13620, South Korea
Santiago de Compostela, 15706, Spain
Valencia, 46010, Spain
Valencia, 46026, Spain
Huddinge, 141 86, Sweden
London, Greater London NW3 2QG, United Kingdom
Manchester, Greater Manchester M15 6SE, United Kingdom
Birmingham, West Midlands B15 2SQ, United Kingdom